Along the same lines as ivacaftor and hypertonic saline, several pharmaceutical groups have been pursuing pharmaceuticals that target other ion channels to improve mucociliary clearance in a cftr -independent manner
June 12, 2024
Mechanism difference Semaglutide (GLP-1 agonist): appetite regulation, satiety, improved glycemic control (New England Journal of Medicine) Tirzepatide (GLP-1/GIP agonist): broader incretin effects, robust appetite/weight effects (New England Journal of Medicine) AOD-9604: targeted fat-metabolism signaling
A shaken peptide vial might look dissolved, but the peptide structure could be compromised, leading to reduced effectiveness
11 This guideline was based on Medline, PubMed, and consensus conference proceedings and categorizes what is mandatory, as well as recommended, for an IC diagnosis
This product should only be handled by qualified, and licensed professionals